Kemwell Biopharma News and Resources

RevOpsis Therapeutics and Kemwell Biopharma Pvt. Ltd. have entered a strategic partnership to accelerate the development of RevOpsis’ lead candidate, RO-104, for the treatment of neovascular age-related macular degeneration (nAMD). The collaboration, announced on June 17, 2024, leverages Kemwell’s contract

Kemwell BioPharma, India’s largest biologics contract development and manufacturing organisation (CDMO), has announced the implementation of the Veeva Vault Quality Management System (QMS) across its development and manufacturing operations. Deepak Gupta, vice president of quality at Kemwell, said, “Veeva is